Additional treatment options for your patients

  • 179,000 patient profiles1
  • ~300 publications2
  • > 300 genes3

About molecular tumour profiles

What is FoundationOne®?

FoundationOne® provides a comprehensive molecular tumour profile which can support doctors in their decisions regarding the treatment of cancer patients by detecting genetic changes associated with cancer.

  • Validated NGS-based analysis of the four main classes of genomic alterations4
  • Sequenzierung der gesamten Kodierungssequenz von 315 Genen und Introns von 28 ausgewählten Genen
  • measurement of TMB and MSI status5

Sample Report

1 Foundation Medicine Press Releases: 2013 2014 2015 2016 2017
2 A search for “Foundation Medicine”[Affiliation] on the NCBI database resulted in 292 publications, as of February 2018. Link (Last Access 21.02.2018)"
3 FoundationOne®Gene List
4 Frampton GM et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013;31(11):1023–1031.
5 Chalmers ZR et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 2017;9(1):34.

TMB: Tumor Mutational Burden
MSI: Micro-satellite Instability

Further information

Targeted therapy

Targeted therapy

Cancers have long been categorized and treated based on the anatomic site of origin, e.g., lung, breast, colon, skin, etc. Oncologists and pathologists are increasingly also focusing on the genomic alterations, in the genes that drive a cancer.

As we understand more about these underlying genetic alterations, cancer may be treated with targeted therapies that specifically attack those changes in a patient’s tumor.

Why?

Why?

Comprehensive approach delivers reliable results

  • Detects all classes of genetic changes – base substitutions, insertions/deletions, copy number variations and gene recombinations.
  • FoundationOne® is a comprehensive tumour profile based on a validation study that confirmed the industry-leading accuracy of the method and was published in a renowned scientific journal.*

Additional treatment options for your patients

  • Standard tests such as FISH and IHC as well as hotspot panels generally recognise only one or two types of clinically relevant changes.
  • FoundationOne® can reveal more targeted treatment options for your patients than standard hotspot panels.*

Saves tissue material and time

  • Requires only a small volume of tissue, including routine biopsy specimens and fine-needle aspirates.*
  • Also even with specimens with a high proportion of non-tumour cells.*

Relevant results summarised in one report

  • All clinically relevant genetic changes detected are compared with targeted therapies and clinical trial programmes on the basis of the current state of scientific knowledge and published clinical data.
  • More than 20 bioinformaticians and scientists with a background in biomedical sciences, as well as state-of-the-art algorithms help ensure that the FoundationOne® report contains the most clinically relevant information for every patient.

* Frampton G., et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013; 31, 1023-31

Order from University Hospital Zurich (USZ), Institute of Pathology and Molecular Pathology

Procedure:

  • The oncologist orders FoundationOne® from USZ.
  • The pathologist sends the tumour block (FFPE) to USZ.
  • The tumour specimen is analysed, and the results are evaluated.
  • USZ sends the report to the oncologist.

Learn more...

Contact us

Please contact USZ if you have any questions or need advice. We look forward to hearing from you.

For patients:
Patients should speak directly to their oncologist if they have questions or require information about the test results.

For oncologists:

Tel: + 41 (43) 253 03 34 E-Mail: fmi.pathologie@usz.ch Fax: + 41 (44) 255 4552

Publishing information

What is FoundationOne®?